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Abstract 
Background: Circulating microRNAs (miRNAs) emerge as novel biomarkers in cardiovascular diseases. Diagnosing 
acute pulmonary embolism (PE) remains challenging due to a diverse clinical presentation and the lack of specific 
biomarkers. Here we evaluate serum miRNAs as potential biomarkers in acute PE.
Methods: We enrolled 30 patients with acute, CT (computed tomography)-angiographically confirmed central 
PE and collected serum samples on the day of emergency room admission (1st day) and from 22 of these patients 
9 months thereafter. For comparison, we examined serum samples from patients with acute non ST-segment eleva-
tion myocardial infarction (NSTEMI, n = 30) and healthy individuals (n = 12).
Results: We randomly selected 16 out of 30 PE patients and screened sera from the acute (1st day) and chronic 
stages (9 months) for 754 miRNAs using microarrays and found 37 miRNAs to be differentially regulated. Across all 
miRNAs, miRNA-1233 displayed the highest fold change (FC) from acute to chronic stage (log2FC 11.5, p < 0.004). We 
validated miRNA-1233 by real-time quantitative polymerase chain reaction (RT-qPCR). In acute PE (1st day) we found 
elevated levels of miRNA-1233 in comparison to NSTEMI (log2FC 5.7, p < 0.0001) and healthy controls (log2FC 7.7, 
p < 0.0001). miRNA-1233 differentiated acute PE from NSTEMI patients and healthy individuals with 90 and 90 % sensi-
tivity, and 100 and 92 % specificity [area under the curve (AUC) 0.95, p < 0.001 and 0.91, p < 0.001], respectively.
Conclusions: This is the first report that identifies a miRNA that allows distinguishing acute PE from acute NSTEMI 
and healthy individuals with high specificity and sensitivity.
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Background
Acute pulmonary embolism (PE) is a common cardio-
vascular emergency with a high incidence of morbidity 
and mortality [1, 2]. Together with deep vein thrombo-
sis (DVT), PE is the third most frequent cardiovascular 
disease in western countries with an annual incidence 
of 100–300 per 100,000 individuals [3]. PE is difficult to 
diagnose and frequently missed due to a variable clini-
cal presentation including dyspnea at rest or on exertion, 
chest pain and syncope [4, 5]. Patients with acute myo-
cardial infarction (MI) also often present chest pain and 
shortness of breath, consequently acute MI is one of acute 
PE’s most frequent differential diagnoses. The work-up 
for diagnosing PE can comprise biomarkers (such as the 
fibrin degradation product D-dimer), echocardiogra-
phy, venous compression ultrasonography and radio-
logic imaging with computed tomography angiography, 
and ventilation–perfusion scintigraphy [1, 6]. Although 
widely used in patients with suspected PE, D-dimer tests 
exhibit a high sensitivity, but fall short of being specific 
for diagnosing acute PE [7]. Hence, the introduction of 
novel biomarkers with a superior diagnostic accuracy 
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MicroRNAs (miRNAs) are small (~22 nucleotides), 
non-coding, single-stranded RNAs which can inhibit pro-
tein synthesis by negatively regulating gene expression via 
translational repression or mRNA degradation [8–10]. 
Often, miRNA expression is cell or tissue specific and their 
expression pattern can be altered upon initiation of patho-
logic processes. miRNAs can be detected in the circulation 
(serum or plasma) in a stable form [11] and thus represent 
attractive biomarkers for cardiovascular diseases [12–22].
In our study, we screened sera of patients with acute 
PE at different time points during the course of disease 
for differentially regulated miRNAs. We validated three 
selected miRNAs by qPCR and then tested their speci-
ficity and sensitivity for accurately diagnosing acute PE. 
This is the first report that identifies a profile of circu-
lating miRNAs that allows distinguishing acute PE from 
acute non ST-segment elevation myocardial infarction 
(NSTEMI), acute DVT, chronic non-thromboembolic 
pulmonary hypertension (PH) and healthy individuals 
with high specificity and sensitivity.
Methods
Patients of the study group
We enrolled patients presenting with acute symptom 
onset at the emergency department at the University 
Hospital of Schleswig–Holstein, Campus Lübeck, Ger-
many who were diagnosed with central PE (location 
of the embolism in the pulmonary trunk and/or main 
pulmonary artery/ies) by CT-pulmonary angiography. 
Serum samples were taken at the emergency department 
on the admission day (1st day), as well as on the third 
and on the fifth day of the hospital stay. We recalled 22 
patients 9 ± 1.5 months after the hospital stay and took a 
fourth serum sample.
Patients of the control groups
For comparison, we enrolled patients that presented at 
the emergency department with acute NSTEMI. Fur-
thermore, we enrolled patients with acute DVT, patients 
with chronic non-thromboembolic PH and healthy indi-
viduals (colleagues in the lab without any current of past 
medical condition).
Ethics, consent and permissions
Patients gave informed consent to participate in this 
study as part of the Lübeck Registry of Structural Heart 
Disease [23], approved by the ethics committee of the 
University of Lübeck (No. 04-041).
Consent to publish
Patients gave informed consent for publishing results of 
this study as part of the Lübeck Registry of Structural 
Heart Disease [23].
RNA isolation
Blood samples were allowed to coagulate at room tem-
perature and then immediately centrifuged at 1500  g 
for 15  min. The supernatant was transferred to RNase/
DNase-free tubes and stored at −80  °C. RNA isolation 
was performed by using a miRNeasy Mini Kit (Qiagen, 
Hilden, Germany) with combining phenol/guanidine-
based lysis and silicamembrane-based purification of 
RNA, according to the manufacturer’s instructions. In 
brief, 300  µl of serum were homogenized in 900  µl of 
QIAzol lysis reagent (Qiagen, Hilden, Germany). After 
adding 240  µl chloroform (Merck Millipore, Germany), 
the homogenate was separated by centrifugation. The 
upper (aqueous) phase was extracted and 100 % ethanol 
(Merck Millipore, Germany) was added. Samples were 
then applied to miRNeasy Mini spin columns. RNA was 
eventually eluted in RNase-free water. To normalize for 
the miRNA content, we supplemented samples with 
10  nM miRNA 39 from Caenorhabditis elegans (cel-
miR-39, Applied Biosystems, Foster City, CA, USA) as 
spiked-in control, after adding the QIAzol, as described 
previously [24, 25].
Serum miRNA profiles
We screened sera from PE patients for 754 miRNAs 
using TaqMan low-density miRNA microarrays (human 
miRNA A V2 and human miRNA B V3, Applied Biosys-
tems, Foster City, CA, USA). Reverse transcription (RT) 
and pre-amplification steps were performed using the 
same volume of total RNA, according to the manufac-
turer’s protocol. Real-time quantitative polymerase chain 
reaction (RT-qPCR) was performed using the 7900 HT 
Fast Real-Time PCR System (Applied Biosystems, Fos-
ter City, CA, USA); results were expressed as Cts (cycle 
threshold, with the baseline set to 0.2).
Validation of findings using miRNA RT‑qPCR
Based on the results from the screening experiments, we 
selected miRNAs for further RT-qPCR validation. After 
RNA extraction, and pre-amplification (carried out as 
described above), individual miRNA expression was 
determined using TaqMan microRNA Assays (Applied 
Biosystems, Foster City, CA, USA), according to manu-
facturer’s instructions. We used the following TaqMan 
probes: hsa-miR-1233-002768, hsa-miR-27a#-002445 
and hsa-miR-134-001186 (Applied Biosystems, Foster 
City, CA, USA). In individual TaqMan microRNA Assays, 
cel-miRNA-39 was used for normalization.
Computational methods
miRNA screening
miRNA array data analysis was performed using R/Bio-
conductor packages [26]. Raw threshold cycle (Ct) values 
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were first processed by replacing ‘Undetermined’ Ct val-
ues with Ct = 50.0 and thereafter filtered in a way that we 
excluded miRNAs where the median Ct was ≤35.0 in at 
least one of the comparison groups (‘acute’ vs. ‘chronic’). 
After filtering, raw Ct values were converted into rela-
tive quantities (RQ) by using a formula RQ = EΔCt, where 
PCR efficiency (E) was assumed to be 100 % [27], reflected 
by a value of two for the base E of the exponential func-
tion. Median normalization was used in order to obtain 
normalized relative quantities (NRQ) by dividing each 
RQ with the overall median of the corresponding sample 
(‘acute’ vs. ‘chronic’). For two-way comparisons, the limma 
[28] t-statistic approach with Benjamini–Hochberg (BH; 
FDR) multiple testing correction [29] was used to select 
the differentially expressed miRNAs from the median-
normalized data. miRNAs were defined as differentially 
expressed if they had a −1 ≥ log2FC ≥ 1 and P value ≤0.15 
across the comparison groups (‘acute’ vs. ‘chronic’).
miRNA validation
Statistical analyses were carried out using GraphPad 
Prism software, version 6 (GraphPad Software, Inc.). 
Results are displayed as mean ± standard error of mean 
(S.E.M.), if not noted otherwise. First, values were tested 
for outliers (ROUT method, Q = 1 %) and for Gaussian 
distribution (D’Agostino-Pearson omnibus normality 
test). For comparing more than two groups, an ordinary 
one-as applied to parametric data. For non-parametric 
data, a Kruskal–Wallis test was performed, followed by a 
Dunn’s test for multiple comparisons. P values of <0.05 
indicated statistical sway ANOVA test, followed by a 
Sidak’s test for multiple comparisons, significance.
ROC curve analyses
All analyses were performed using R [30]. The diagnostic 
accuracy of individual miRNAs and their combinations 
was assessed using logistic regression and multinomial 
logistic regression analysis, respectively. The trade-offs 
between the specificity and sensitivity measures were 
then assessed using the receiver operating characteris-
tic (ROC) curves (pROC package [31]). The area under 
the ROC curve (AUC) was used as summary measure to 
average the detection accuracy across the spectrum of 
test values. The AUC for each prediction was compared 
to random classifier (AUC  =  0.5) using the Wilcoxon 
signed rank test, as implemented in MKmisc http://cran-
tastic.org/packages/MKmisc. The maximum value of 
the Youden’s index (J = Sensitivity + Specificity − 1) for 
each ROC curve was used for selecting the optimal cut-
off point for the diagnostic tests. The positive likelihood 
ratio (LR+) was calculated as sensitivity/(1 − specificity), 




We enrolled 30 patients (age 62 ± 14, mean ± SD, 57 % 
male, all Caucasians) who presented with acute symp-
tom onset at the emergency department and were here 
diagnosed with central PE (location of the embolism in 
the pulmonary trunk and/or main pulmonary artery/
ies) by computed tomography (CT)-pulmonary angiog-
raphy (Table 1). The majority of patients presented with 
shortness of breath (81  %) and/or chest pain (33  %). In 
most patients the cause of PE remained idiopathic. The 
time course of biomarkers D-dimers, high sensitive tro-
ponin T and n-terminal (nt) pro brain natriuretic peptide 
(BNP) is displayed in Fig.  1. Serum samples were taken 
at the emergency department on the admission day (1st 
day), as well as on the third and fifth day of the hospi-
tal stay. We re-called 22 (50 % male patients) of these 30 
patients 9 ± 1.5 months (mean ± SD) after the hospital 
stay and collected a fourth serum sample (9 months). For 
comparison, we enrolled 30 age- and gender-matched 
Table 1 Patients’ characteristics
Characteristics of acute pulmonary embolism (PE) patients at the time of the 
emergency room presentation (1st day)
CTA computed tomography (pulmonary) angiography, CPR cardiopulmonary 
resuscitation, DVT deep vein thrombosis, BMI body mass index, US ultrasound, 
SD standard deviation
n 30
Age (mean ± SD) 62 ± 14
Male 17/30 (57 %)
CTA confirmed central PE (pulmonary trunk, main pulmo-
nary arteries)
100 %
Risk stratefication (PE-related early mortality rate)
 High (>15 %) 4/30 (13 %)
 Intermediate (3–15 %) 15/30 (50 %)
 Low (<1 %) 11/30 (37 %)
Symptoms
 Dyspnoea 24/30 (81 %)
 Chest pain 10/30 (33 %)
 Cough 3/30 (10 %)
 Syncope 3/30 (10 %)
 Haemoptysis 2/30 (7 %)
 Collaps with subsequent CPR 4/30 (13 %)
Idiopathic DVT/PE 13/30 (43 %)
Secondary DVT/PE
 Malignancy 4/30 (13 %)
 Post surgery 4/30 (13 %)
 Immobilisation 2/30 (7 %)
 Thrombophilia 1/30 (3 %)
 Previous DVT/PE 2/30 (7 %)
 Oral contraceptive therapy 2/30 (7 %)
 Obesity (BMI ≥ 30 kg/m2) 12/30 (40 %)
US confirmed DVT 25/30 (83 %)
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patients that presented at the emergency department 
with acute non ST-segment elevation myocardial infarc-
tion (NSTEMI, mean age ±  SD: 64 ±  13, 57  % males, 
Table  2). Furthermore, we enrolled six age-matched 
patients with acute DVT (mean age ± SD: 66 ± 10, 67 % 
males) confirmed by compression ultrasonography with-
out any clinical or apparative signs of concomitant PE 
(no dyspnea, no chest pain, normal ECG, normal right 
heart echocardiography, normal blood gas analysis), 15 
age-matched patients with chronic non-thromboembolic 
pulmonary hypertension (PH, mean age ± SD: 65 ± 13, 
47 % males), and 12 healthy individuals (mean age ± SD: 
31 ± 6, 50 % males).
Serum miRNA screening and validation
We first randomly selected 16 out of 30 PE patients and 
screened their sera from the acute phase (1st day) and 
from the chronic stage (9 months) for 754 miRNAs using 
TaqMan human miRNA arrays. We found 37 miRNAs 
to be differentially regulated with a nominally significant 
P value (<0.05, 1st day vs. 9 months, Fig. 2a). Across all 
screened miRNAs, miRNA-1233 displayed the high-
est fold change at the acute (1st day) in comparison to 
the chronic stage (9  months) (log2FC 11.5, P  <  0.004). 
We then validated our array findings on all enrolled PE 
patients from all time points by TaqMan-based miRNA 
real-time quantitative polymerase chain reaction (RT-
qPCR). We confirmed that miRNA-1233 displayed high-
est serum levels on the first day, its levels then decreased 
on the third and fifth day and were lowest at the chronic 
stage of the disease (FC 3.7 on 1st day vs. 9  months, 
p  <  0.01, Fig.  2b). Our findings show that miRNA-1233 
was up-regulated in the serum of acute PE patients, 
Fig. 1 Biomarker time course. Levels of the biomarkers D-Dimers, 
high sensitive (hs) TroponinT and n-terminal (nt) pro brain natriuretic 
peptide (BNP) during the course of pulmonary embolism (PE, 1st day: 
presentation at the emergency department, 3rd and 5th day during 
the hospital stay (n = 30) and 9 ± 1.5 months thereafter (n = 22), 
mean ± SEM, *p < 0.05, **p < 0.01, ****p < 0.0001)
Table 2 Patients’ characteristics
Patients’ characteristics of the acute pulmonary embolism (PE) and acute non 
ST-segment elevation myocardial infarction (NSTEMI) groups
BMI body mass index, LV-EF left ventricular ejection fraction, CV cardiovascular, 
CAD coronary artery disease, PCI percutaneous coronary intervention, CABG 
coronary artery bypass grafting, MI myocardial infarction
Acute PE Acute NSTEMI p
Age (y) 62 ± 14 64 ± 13 0.57
Male gender (%) 57 57 1.00
Onset to sampling < 24 h (%) 63 70 0.58
BMI (kg/m2) 30.6 ± 7.7 27.9 ± 9.3 0.23
LV-EF (%) 60 ± 2 57 ± 7 0.03
CV risk factors
Hypertension (%) 63 81 0.15
Hyperlipidemia (%) 17 41 0.04
Smoking (%) 10 52 <0.001
Diabetes mellitus (%) 20 22 0.75
Positive family history (%) 3 33 <0.01
CV history
Non-obstructive CAD (%) 17 3 0.09
Obstructive CAD (%) 0 6 0.15
Previous PCI/CABG (%) 0 6 0.15
Previous MI (%) 0 6 0.15
Resuscitation (%) 0 0 1.00
Atrial fibrillation (%) 0 3 0.31
Previous stroke (%) 3 3 1.00
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indicating that it could represent a marker for diagnosing 
acute PE.
Sensitivity and specificity of miRNA‑1233 for diagnosing 
acute PE
We then tested miRNA-1233 specificity and sensitiv-
ity for diagnosing acute PE and compared miRNA-
1233 serum levels from acute PE patients to levels 
from patients with acute NSTEMI, acute DVT, chronic 
non-thromboembolic PH and healthy individuals by 
TaqMan-based miRNA RT-qPCR. Patients’ characteris-
tics are shown in Table 2. We found significantly higher 
levels of miRNA-1233 in the serum of acute PE patients 
in comparison to all other groups (PE 1st day FC 206.3, 
NSTEMI FC 3.9, DVT FC 1, PH FC 5.4 vs. healthy, 
Fig.  2c). Receiver operating characteristic (ROC) analy-
sis revealed that miRNA-1233 differentiated acute PE 
(1st day) from acute NSTEMI, DVT, PH patients and 
healthy controls with high sensitivity (90, 97, 90, and 
90 %, respectively) and specificity (100, 100, 93, and 92 %, 
Fig. 2 miRNA-1233. a microRNA (miRNA) array screening. We randomly selected 16 out of 30 pulmonary embolism (PE) patients and screened their 
sera from the acute (1st day) and chronic stage (9 months) for 754 miRNAs. The 37 most differentially expressed miRNAs (nominal P value ≤ 0.05) 
were displayed. miRNA-1233 (red dot) displayed the highest fold change on the 1st day (log2FC 11.5 on 1st day vs. 9 months, p < 0.004) and was 
consequently subjected to real-time quantitative polymerase chain reaction (RT-qPCR) validation. b miRNA RT-qPCR validation. Serum miRNA-1233 
levels during the time course of acute PE (1st day: presentation at the emergency department, 3rd and 5th day during the hospital stay (n = 30) 
and 9 ± 1.5 months thereafter (n = 22). Values represent relative levels with the “9 months” group set as 1 (mean ± SEM, **p < 0.01). c Serum 
miRNA-1233 levels from acute pulmonary embolism patients (APE, 1st day, n = 30) in comparison to patients with acute non ST-segment elevation 
myocardial infarction (NSTEMI, n = 30), acute deep vein thrombosis without concomitant PE (DVT, n = 6), chronic non-thromboembolic pulmo-
nary hypertension (PH, n = 15) and healthy individuals (n = 12). Values represent relative levels with the “healthy” group set as 1 (mean ± SEM, 
***p < 0.001, ****p < 0.0001). d Receiver operating characteristic (ROC) curve analysis for miRNA-1233 to discriminate acute PE (1st day) from acute 
NSTEMI (red line, area under the curve (AUC) 0.95, p < 0.001, sensitivity 90 % and specificity 100 %), acute DVT (blue line, AUC 0.99, p < 0.001, sensitiv-
ity 97 % and specificity 100 %), chronic PH (orange line, AUC 0.91, p < 0.001, sensitivity 90 % and specificity 93 %) and healthy individuals (green line, 
AUC 0.91, p < 0.001, sensitivity 90 % and specificity 92 %)
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respectively, Fig.  2c). Detailed ROC statistics are shown 
in Table  3. Taken together, miRNA-1233 distinguished 
acute PE (1st day) from acute NSTEMI, its most frequent 
differential diagnosis, with high specificity and sensitivity.
miRNA profile/signature
We further identified two additional miRNAs, miRNA-
27a and miRNA-134, which exhibited highest serum 
levels in PE patients on the first day and lowest levels at 
9 months (FC 3.6, 4.1 on 1st day vs. 9 months, p < 0.05, 
p  <  0.01, respectively, Fig.  3a). Similar to miRNA-1233, 
we found significantly higher levels of miRNAs -27a and 
134 in the serum of acute PE patients in comparison to all 
other groups (PE 1st day FC 34.1, 14.8; NSTEMI FC 2.3, 
2.5; DVT FC 1.4, 0.3; PH FC 7.5, 3.3 vs. healthy, respec-
tively, Fig.  3b). ROC analysis revealed that miRNA-27a 
differentiated acute PE (1st day) from NSTEMI, DVT, PH 
patients and healthy controls with 63, 73, 67, and 67  % 
sensitivity, and 89, 100, 80, and 92 % specificity, respec-
tively (Fig.  3c). Accordingly, miRNA-134 differentiated 
acute PE (1st day) from NSTEMI, DVT, PH patients and 
healthy controls with 83, 80, 70, and 83 % sensitivity, and 
64, 100, 73, and 83  % specificity, respectively (Fig.  3c). 
Detailed ROC statistics are shown in Table  3. We then 
tested, whether or not a combination of miRNAs (serum 
miRNA profile/signature) improved diagnostic sensitivity 
Table 3 Receiver operating characteristic curves
Receiver operating characteristic (ROC) curves. Cut-off is defined as the Youden’s index which represents the point on the curve furthest away from the 45 degree line
AUC area under the curve, CI confidence interval, LR + positive likelihood ratio, LR- negative likelihood ratio, miR microRNA, PE pulmonary embolism, NSTEMI acute 
non-ST segment myocardial infarction, DVT acute deep vein thrombosis without concomitant PE, PH chronic non-thromboembolic pulmonary hypertension
AUC 95 % CI p Cut‑off Sensitivity (%) 95 % CI Specificity (%) 95 % CI LR+ LR−
Acute PE vs. healthy
miR-27a 0.79 0.65–0.93 <0.01 0.63 67 50–83 92 75–100 8 0.4
miR-134 0.84 0.71–0.96 <0.001 0.51 83 70–97 83 58–100 5 0.2
miR-1233 0.91 0.82–0.99 <0.001 0.53 90 77–100 92 75–100 10.8 0.1
miR-27a + miR-134 0.88 0.78–0.98 <0.001 0.47 90 77–100 83 58–100 5.4 0.1
miR-27a + miR-1233 0.89 0.79–0.99 <0.001 0.48 97 90–100 83 58–100 5.8 0
miR-134 + miR-1233 0.88 0.77–0.98 <0.001 0.40 93 83–100 75 50–100 3.7 0
miR-27a + miR-134 + miR-1233 0.90 0.81–0.99 <0.001 0.50 90 80–100 83 58–100 5.4 0.1
Acute PE vs. NSTEMI
miR-27a 0.78 0.66–0.90 <0.001 0.46 63 43–80 89 79–100 5.9 0.4
miR-134 0.78 0.66–0.90 <0.001 0.74 83 70–97 64 46–82 2.3 0.3
miR-1233 0.95 0.89–1.00 <0.001 0.55 90 80–100 100 100–100 ∞ 0.1
miR-27a + miR-134 0.80 0.68–0.91 <0.001 0.34 87 73–97 61 43–79 2.2 0.2
miR-27a + miR-1233 0.96 0.91–1.00 <0.001 0.69 90 77–100 100 100–100 ∞ 0.1
miR-134 + miR-1233 0.95 0.89–1.00 <0.001 0.54 90 77–100 100 100–100 ∞ 0.1
miR-27a + miR-134 + miR-1233 0.97 0.93–1.00 <0.001 0.71 90 77–100 100 100–100 ∞ 0.1
Acute PE vs. DVT
miR-27a 0.83 0.67–0.98 <0.05 0.79 73 57–90 100 100–100 ∞ 0.3
miR-134 0.84 0.72–0.99 <0.01 0.74 80 67–93 100 100–100 ∞ 0.2
miR-1233 0.99 0.97–1.0 <0.001 0.72 97 90–100 100 100–100 ∞ 0
miR-27a + miR-134 0.92 0.83–1.0 <0.001 0.63 87 73–97 100 100–100 ∞ 0.1
miR-27a + miR-1233 0.99 0.97–1.0 <0.001 0.72 97 90–100 100 100–100 ∞ 0
miR-134 + miR-1233 0.99 0.97–1.0 <0.001 0.72 97 90–100 100 90–100 ∞ 0
miR-27a + miR-134 + miR-1233 0.99 0.97–1.0 <0.01 0.72 97 90–100 100 100–100 ∞ 0
Acute PE vs. PHT
miR-27a 0.66 0.50–0.82 0.085 0.66 67 50–83 80 60–100 3.3 0.4
miR-134 0.67 0.51–0.83 0.062 0.61 70 53–87 73 47–93 2.6 0.4
miR-1233 0.91 0.83–0.99 <0.001 0.43 90 80–100 93 80–100 13.5 0.1
miR-27a + miR-134 0.66 0.50–0.82 0.085 0.59 70 53–87 73 47–93 2.6 0.4
miR-27a + miR-1233 0.92 0.84–1.0 <0.001 0.42 90 77–100 93 80–100 13.5 0.1
miR-134 + miR-1233 0.91 0.83–0.99 <0.001 0.42 90 77–100 93 80–100 13.5 0.1
miR-27a + miR-134 + miR-1233 0.90 0.81–0.99 <0.001 0.46 90 80–100 93 80–100 13.5 0.1
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and specificity. Neither combining miRNA-1233 with 
either miRNA-27a or miRNA-134 (Fig. 4a; Table 3), nor 
combining all three miRNAs improved sensitivity and 
specificity for accurately differentiating acute PE from 
healthy individuals and acute NSTEMI patients (Fig. 4b; 
Table  3). We then directly compared all three miRNA 
and found that miRNA-1233 was always superior to 
miRNAs-27a and miRNA-134 for accurately distinguish-
ing acute PE from acute NSTEMI, acute DVT and PH 
patients and from healthy individuals (Fig.  4c; Table  3). 
In summary, miRNA-1233 alone yielded a superior capa-
bility of distinguishing acute PE from healthy individuals 
Fig. 3 miRNA-27a and 134. a Serum miRNA-27a and 134 levels during the time course of acute pulmonary embolism (APE, 1st day: presentation at 
the emergency department, 3rd and 5th day during the hospital stay (n = 30) and 9 ± 1.5 months thereafter (n = 22). Values represent relative lev-
els with the pulmonary embolism (PE) “9 months” group set as 1 (mean ± SEM, *p < 0.05, **p < 0.01). b Serum miRNA-27a and 134 levels from acute 
PE patients (APE, 1st day, n = 30) in comparison to patients with acute non ST-segment elevation myocardial infarction (NSTEMI, n = 30), acute 
deep vein thrombosis without concomitant PE (DVT, n = 6), chronic non-thromboembolic pulmonary hypertension (PH, n = 15) and healthy indi-
viduals (n = 12). Values represent relative levels with the “healthy” group set as 1 (mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001). c ROC (Receiver 
operating characteristic) curve analysis for miRNA-27a and 134 to discriminate acute PE (1st day) from acute NSTEMI (red line, area under the curve 
(AUC) 0.78, 0.78, p < 0.001, < 0.001, respectively), acute DVT (blue line, AUC 0.83, 0.84, p < 0.05, < 0.01, respectively), chronic PH (orange line, AUC 0.66, 
0.67, p = 0.09, 0.06, respectively) and healthy individuals (green line, AUC 0.79, 0.84, p < 0.01, < 0.001, respectively)
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and the described diseases in comparison to miRNA-27a 
and miRNA-134 (Table 3). A signature, comprising miR-
NAs-1233, 27a and 134 could not further increase sensi-
tivity and specificity, and was consequently not superior 
to miRNA-1233 alone.
Discussion
A timely diagnosis of PE remains to be a challeng-
ing clinical problem [3, 32]. In fact, recent studies have 
revealed that up to one third of all PE cases are missed 
at the emergency department [33]. Here, we screened 
sera of PE patients for more than 750 miRNA by using 
miRNA arrays and found significantly elevated levels of 
miRNA-1233 in patients with acute PE (vs. chronic PE). 
We validated these array findings by individual TaqMan 
qPCR and found—as compared to acute PE patients—
markedly lower miRNA-1233 levels in patients with 
NSTEMI, DVT, PH, as well as in healthy individuals. 
Importantly, miRNA-1233 distinguished acute PE from 
acute NSTEMI, its most frequent differential diagnosis, 
with high specificity and sensitivity.
Pulmonary embolism is a frequent emergency affecting 
100–300/100,000 individuals per year in industrialized 
nations [3]. Like acute MI patients, patients with acute 
PE present symptoms like chest pain and shortness of 
breath. Consequently, acute PE and acute MI are among 
the most frequent differential diagnosis for shortness 
of breath and chest pain [3, 4], and distinguishing these 
diseases can be difficult due to a similar clinical presen-
tation. However, distinguishing PE from MI early on is 
crucial because these different pathologies require dis-
tinct treatments, which, when applied in a timely fashion, 
significantly enhance patient survival [34–37]. PE treat-
ment is mainly conservative and focuses on anticoagula-
tion, while in MI an invasive re-vascularization therapy is 
often pursued [38].
Fig. 4 Receiver operating characteristic curve analysis. ROC (Receiver operating characteristic) curve analysis for a combining two microRNAs 
(miRNA) or b all three miRNAs to discriminate acute pulmonary embolism (PE, 1st day) from acute non-ST segment myocardial infarction (NSTEMI, 
red line), acute deep vein thrombosis without concomitant PE (DVT, blue line), chronic non-thromboembolic pulmonary hypertension (PH, orange 
line) and healthy individuals (green line). c ROC curve analysis for comparing miRNAs (green line: miRNA-1233, red line: miRNA-134, blue line: miRNA-
27a) to discriminate acute PE (1st day) from acute NSTEMI, acute DVT without concomitant PE, chronic non-thromboembolic PH and healthy 
individuals
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To date, there are no specific biomarkers for an early 
accurate detection of acute PE. High sensitivity troponins 
and D-dimers are often used for diagnosing MI or PE, 
respectively. However, these markers do not perfectly 
discriminate the two conditions. Specifically, elevated 
D-dimer levels can also be found in MI patients [39], as 
well as in a number of other conditions [1]. Vice versa, 
elevated troponin levels can also be detected in acute PE, 
especially if the right heart is affected (acute cor pulmo-
nale) [40].
Rapidly and accurately diagnosing acute PE would 
be an extremely helpful tool, especially at emergency 
departments. Ideally, miRNA-1233 could identify acute 
PE patients early as a bedside test so that correct treat-
ment could be initiated timely, consequently reducing 
mortality and morbidity. As of now, most laboratories 
use RT-qPCR-based methods for detecting serum miR-
NAs. RT-qPCR is very sensitive on one hand, but also 
difficult to standardize on the other. To date, a house 
keeping miRNA to normalize miRNA content to is lack-
ing. The current practice of supplementing external con-
trols (for instance spiking of miRNAs for normalization 
in PCR-based measurements) might not be sufficient 
enough to provide an accurate bedside measurement of 
circulating miRNAs. For the clinical routine, well-defined 
cutoff values and reliable measurements are most crucial 
and would be needed.
To date, there is one other study that also evaluated 
serum miRNAs for diagnosing PE [18]. We reproduced 
the finding of Xiao et al. that miRNA-134 is up-regulated 
in acute PE patients making miRNA-134 an even more 
promising marker, since our findings are the first replica-
tion on an independent cohort. However, the study did 
not report on miRNA-1233 or on miRNA-27a, and nor 
did it show miRNA-134 specificity to distinguish PE from 
other relevant differential diagnosis like NSTEMI.
Interpretations of our study results are limited mainly 
due to (1) a rather small sample size (n = 30 in each the 
PE and NSTEMI group) and (2) a highly selected, very 
morbid group of PE patients with a high thrombus bur-
den. Our findings need to be replicated on a larger cohort 
of patients and also on less morbid PE patients with 
peripheral rather than central emboli.
Conclusions
Circulating miRNA-1233 allows distinguishing acute PE 
from acute NSTEMI and healthy individuals with high 
specificity and sensitivity, and consequently appears to be 
a promising marker for accurately diagnosing acute PE.
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